Amivantamab, a bispecific antibody targeting EGFR and mesenchymal-epithelial transition (MET) receptor, has a low-level core fucosylation and enhanced FcγRIIIa binding leading to ADCC induced cancer cell death. The gene discussed is FCGR3A; the disease is cancer.